Dailypharm Live Search Close

JW¡¯s ¡®Actemra¡¯ reviewed for reimbursement as COVID-19 Tx

By Lee, Tak-Sun | translator Alice Kang

22.02.24 06:00:48

°¡³ª´Ù¶ó 0
The arthritis treatment is being widely used off-label to treat severe COVID-19

NHIS starts negotiations to reduce patient burden of paying ₩340,000 per shot



The government is reviewing providing nsurance benefits to JW Pharmaceutical¡¯s rheumatoid arthritis treatment ¡®Actemra¡¯ (tocilizumab)¡¯ for the treatment of COVID-19.

This is because the drug, which is being often used in Korea off-label to treat patients with severe COVID-19, is increasing patient burden due to its non-reimbursed cost unlike other insured COVID-19 treatments like Remdesivir or Regkirona.

Also, due to its shortage in supply, the medical community has asked the government to purchase Actemra like other COVID-19 treatments.

According to the NHIS webpage on the 23rd, the authorities have conducted negotiations with JW Pharmaceutical on providing he

Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)